JOSE ANTONIO
IRIBARREN LOYARTE
PROFESORADO AGREGADO
![Foto de JOSE ANTONIO](/img/nophoto.png)
![Foto de Hospital Universitario Virgen de las Nieves](/img/noimage_org.png)
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublications in collaboration with researchers from Hospital Universitario Virgen de las Nieves (19)
2023
-
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort
International Journal of Infectious Diseases, Vol. 137, pp. 134-143
-
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Frontiers in Cellular and Infection Microbiology, Vol. 13
2022
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria
Open Forum Infectious Diseases, Vol. 9, Núm. 9
2021
-
Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008–2017)
Mayo Clinic Proceedings, Vol. 96, Núm. 1, pp. 132-146
2020
-
Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial
Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Role of age and comorbidities in mortality of patients with infective endocarditis
European Journal of Internal Medicine, Vol. 64, pp. 63-71
2018
-
Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis
Journal of Infection and Chemotherapy, Vol. 24, Núm. 7, pp. 555-562
-
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Open Forum Infectious Diseases, Vol. 5, Núm. 1
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
2017
-
Infective endocarditis in patients with cancer: A consequence of invasive procedures or a harbinger of neoplasm? A prospective, multicenter cohort
Medicine (United States), Vol. 96, Núm. 38
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Current epidemiology and outcome of infective endocarditis: A multicenter, prospective, cohort study
Medicine (United States), Vol. 94, Núm. 43
-
Left-sided infective endocarditis in patients with liver cirrhosis
Journal of Infection, Vol. 71, Núm. 6, pp. 627-641
2009
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis
Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152
-
The Spanish HIV BioBank: A model of cooperative HIV research
Retrovirology, Vol. 6
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
AIDS, Vol. 22, Núm. 2